HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination.
The effect of vaccinating patients with sustained undetectable HIV-1 viremia (VL) achieved with highly active antiretroviral therapy was prospectively investigated. During the 1998 influenza immunization period, 39 HIV-1-infected patients who showed a VL<20 copies/ml for at least 6 months before the study entry date were vaccinated for influenza. Twenty-two vaccinees were immunized at entry. Seventeen controls were followed for 4 weeks after entry, crossing over then to the vaccination group. The proportion of patients with undetectable VL was not significantly different between the vaccination and control groups 2 and 4 weeks after entry. Therefore, influenza immunization of patients with undetectable viremia achieved with highly active antiretroviral therapy does not seem to affect VL.
Servicio de Medicina Interna, Hospital Universitario Virgen de Valme, Seville, Spain. jmacias@cica.es
J
J
Macías
J A
JA
Pineda
M
M
Leal
M A
MA
Abad
J
J
Delgado
R
R
Rosa
A
A
Rubio
A
A
Sánchez-Quijano
E
E
Lissen
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018592:Cross-Over Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy / Q000276:immunology*; D014779:Virus Replication / Q000187:drug effects
D007252:Influenza Vaccines; D012367:RNA, Viral